Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

165
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
165
Psychosurgery01:30

Psychosurgery

54
Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
54
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

149
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
149
Altered States of Awareness01:06

Altered States of Awareness

184
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
184
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

248
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
248
Psychodynamic Therapy01:29

Psychodynamic Therapy

65
Psychodynamic therapies emphasize the exploration of unconscious processes and early childhood experiences as fundamental contributors to psychological difficulties. These therapies, deeply rooted in Freud's psychoanalytic theory, aim to uncover and resolve unconscious conflicts, granting individuals insights that promote emotional and behavioral healing. Contemporary psychodynamic approaches have evolved, integrating a broader range of influences and methodologies while still valuing the...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relation between observer-rated depressive symptoms and patient-rated quality of life after six weeks of antidepressant treatment: pooled patient-level analysis of mirtazapine trials.

BJPsych open·2026
Same author

The therapist effect in adult psychotherapy: a systematic scoping review of reviews.

Psychotherapy research : journal of the Society for Psychotherapy Research·2026
Same author

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Increased Antidepressant Use after Intensive Care for Aneurysmal Subarachnoid Haemorrhage: A Machine-Learning-Enhanced Propensity-Matched Nationwide Cohort Study.

Neurocritical care·2026
Same author

The serotonin transporter and the serotonin 1B receptor in relation to social cognition in healthy adults.

EJNMMI research·2026
Same author

Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression.

BMC medical education·2026
Same journal

[Access to health data for research].

Lakartidningen·2026
Same journal

[CANVAS and RFC1-related disease - a broad clinical spectrum from cough and neuropathy to cerebellar ataxia].

Lakartidningen·2026
Same journal

[Choosing wisely in Swedish neuroradiology].

Lakartidningen·2026
Same journal

[Asthma among athletes - prevalence, diagnosis and treatment].

Lakartidningen·2026
Same journal

[Minimally invasive surgery for colorectal cancer was introduced in a safe and well controlled manner].

Lakartidningen·2026
Same journal

[Modified Valsalva maneuver induced an asymptomatic polymorphic ventricular tachycardia].

Lakartidningen·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K

[Psychedelic psychiatry].

Evana López1, Hampus Yngwe2, Maria Beckman3

  • 1forskningsassistent, läkare, Akademiska sjukhuset; institutionen för klinisk neurovetenskap, Karolinska institutet, Stockholm.

Lakartidningen
|April 4, 2024
PubMed
Summary
This summary is machine-generated.

Psilocybin, a psychedelic compound, shows promise for treating depression and anxiety, offering potential relief for patients unresponsive to traditional therapies. Early studies indicate it is safe and effective, with ongoing research exploring its role in standard healthcare.

More Related Videos

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.6K
Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

1.5K

Related Experiment Videos

Last Updated: Jun 29, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.6K
Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

1.5K

Area of Science:

  • Psychiatry and Neuroscience
  • Pharmacology

Background:

  • Increasing interest in psychedelic compounds for psychiatric conditions like depression, anxiety, and substance use disorders.
  • Existing treatments are not effective for all patients, with up to a third experiencing persistent depression.
  • Conventional treatments can be lengthy and accompanied by adverse side effects.

Approach:

  • Focus on psilocybin, a serotonin-2A-receptor agonist.
  • Review of recent findings from Phase II studies on psilocybin treatment for depression.
  • Mention of an ongoing Phase III study to further evaluate efficacy and safety.

Key Points:

  • Psilocybin administration, even a single dose, has demonstrated significant reductions in depression and anxiety symptoms.
  • Observed therapeutic effects can persist for several weeks post-administration.
  • Phase II clinical trials suggest psilocybin is a safe and effective treatment option for depression.

Conclusions:

  • Psilocybin-based therapies present a cautiously optimistic outlook for psychiatric treatment.
  • Further research, including Phase III trials, is crucial to determine psilocybin's place in standard medical care.
  • The potential for psilocybin to offer rapid and sustained relief warrants continued investigation.